Jeffrey R Holzberg1, Ran Jin, Ngoc-Anh Le, Thomas R Ziegler, Elizabeth M Brunt, Craig J McClain, Juna V Konomi, Gavin E Arteel, Miriam B Vos. 1. *School of Medicine†Department of Pediatrics, School of Medicine, Emory University, Atlanta‡Biomarker Core Laboratory, Atlanta Veterans Affairs Medical Center, Decatur, GA§Department of Pathology and Immunology, School of Medicine, Washington University, Saint Louis, MO||Department of Pharmacology and Toxicology¶Department of Medicine, University of Louisville, Louisville, KY#Nutrition and Health Sciences Program/GDBBS, Emory University**Children's Healthcare of Atlanta, Atlanta, GA.
Abstract
OBJECTIVE: The aim of the present study was to examine the association between plasminogen activator inhibitor-1 (PAI-1), an acute phase protein strongly associated with cardiovascular disease risk, and adiposity, insulin resistance, and inflammation among overweight and obese children with a wide range of hepatic steatosis. METHODS: Plasma PAI-1 levels were measured in a prospectively recruited cohort of 39 overweight or obese children who underwent comprehensive anthropometric assessment and metabolic measurements. Hepatic steatosis was quantified using magnetic resonance spectroscopy and participants were divided into 3 groups based on whether they had normal hepatic steatosis (<5%), low hepatic steatosis (≥5%-10%), and high hepatic steatosis (>10%). RESULTS: Plasma PAI-1 levels significantly increased across the severity of hepatic steatosis in overweight and obese children, and this association was independent of body mass index z score, visceral fat, insulin resistance, and inflammatory markers (P < 0.05). CONCLUSION: Hepatic steatosis in children is positively associated with circulating levels of PAI-1 independent of body mass index, insulin resistance, and inflammatory markers. Further studies are needed to clarify the potential role of PAI-1 as a therapeutic target in pediatric nonalcoholic fatty liver disease.
OBJECTIVE: The aim of the present study was to examine the association between plasminogen activator inhibitor-1 (PAI-1), an acute phase protein strongly associated with cardiovascular disease risk, and adiposity, insulin resistance, and inflammation among overweight and obesechildren with a wide range of hepatic steatosis. METHODS: Plasma PAI-1 levels were measured in a prospectively recruited cohort of 39 overweight or obesechildren who underwent comprehensive anthropometric assessment and metabolic measurements. Hepatic steatosis was quantified using magnetic resonance spectroscopy and participants were divided into 3 groups based on whether they had normal hepatic steatosis (<5%), low hepatic steatosis (≥5%-10%), and high hepatic steatosis (>10%). RESULTS: Plasma PAI-1 levels significantly increased across the severity of hepatic steatosis in overweight and obesechildren, and this association was independent of body mass index z score, visceral fat, insulin resistance, and inflammatory markers (P < 0.05). CONCLUSION:Hepatic steatosis in children is positively associated with circulating levels of PAI-1 independent of body mass index, insulin resistance, and inflammatory markers. Further studies are needed to clarify the potential role of PAI-1 as a therapeutic target in pediatric nonalcoholic fatty liver disease.
Authors: Giridhar Kanuri; Astrid Spruss; Sabine Wagnerberger; Stephan C Bischoff; Ina Bergheim Journal: Lab Invest Date: 2011-03-21 Impact factor: 5.662
Authors: Li-Jun Ma; Su-Li Mao; Kevin L Taylor; Talerngsak Kanjanabuch; YouFei Guan; YaHua Zhang; Nancy J Brown; Larry L Swift; Owen P McGuinness; David H Wasserman; Douglas E Vaughan; Agnes B Fogo Journal: Diabetes Date: 2004-02 Impact factor: 9.461
Authors: J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff Journal: Proc Natl Acad Sci U S A Date: 1992-08-01 Impact factor: 11.205
Authors: Lucia Pacifico; Michele Di Martino; Antonio De Merulis; Mario Bezzi; John Frederick Osborn; Carlo Catalano; Claudio Chiesa Journal: Hepatology Date: 2013-12-23 Impact factor: 17.425
Authors: Catherine C Cohen; Eduardo Castillo-Leon; Alton B Farris; Shelley A Caltharp; Rebecca L Cleeton; Elizabeth M Sinclair; Diane E Shevell; Morten A Karsdal; Mette Juul Fisker Nielsen; Diana J Leeming; Miriam B Vos Journal: Hepatol Commun Date: 2021-07-08
Authors: Richard D Khusial; Catherine E Cioffi; Shelley A Caltharp; Alyssa M Krasinskas; Adina Alazraki; Jack Knight-Scott; Rebecca Cleeton; Eduardo Castillo-Leon; Dean P Jones; Bridget Pierpont; Sonia Caprio; Nicola Santoro; Ayman Akil; Miriam B Vos Journal: Hepatol Commun Date: 2019-08-13
Authors: Emily R Perito; Veeral Ajmera; Nathan M Bass; Philip Rosenthal; Joel E Lavine; Jeffrey B Schwimmer; Katherine P Yates; Anna Mae Diehl; Jean P Molleston; Karen F Murray; Ann Scheimann; Ryan Gill; David Glidden; Bradley Aouizerat Journal: Hepatol Commun Date: 2017-07-17
Authors: Miriam B Vos; Ran Jin; Juna V Konomi; Rebecca Cleeton; Jessica Cruz; Saul Karpen; Dellys Soler Rodriguez; Jennifer K Frediani; Courtney McCracken; Jean Welsh Journal: Pilot Feasibility Stud Date: 2018-06-05